AXGN Quote, Financials, Valuation and Earnings

Electromed has a net margin of -7.9% compared to Axogen's net margin of 12.06%. Axogen's return on equity of -7.2% beat Electromed's return on equity of 16.57%.

Axogen has a consensus price target of $24.43, signalling upside risk potential of 120.67%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 88.3%. Given that Axogen has higher upside potential than Electromed, analysts believe Axogen is more attractive than Electromed.

Axogen has a beta of 1.195, which suggesting that the stock is 19.457% more volatile than S&P 500. In comparison Electromed has a beta of 0.460, suggesting its less volatile than the S&P 500 by 53.993%.

Axogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axogen pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Axogen quarterly revenues are $48.6M, which are larger than Electromed quarterly revenues of $15.7M. Axogen's net income of -$3.8M is lower than Electromed's net income of $1.9M. Notably, Axogen's price-to-earnings ratio is -- while Electromed's PE ratio is 24.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axogen is 2.55x versus 2.87x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX has a net margin of -7.9% compared to Axogen's net margin of -14.17%. Axogen's return on equity of -7.2% beat IRIDEX's return on equity of -218.69%.

Axogen has a consensus price target of $24.43, signalling upside risk potential of 120.67%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 104.08%. Given that Axogen has higher upside potential than IRIDEX, analysts believe Axogen is more attractive than IRIDEX.

Axogen has a beta of 1.195, which suggesting that the stock is 19.457% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.692, suggesting its less volatile than the S&P 500 by 30.819%.

Axogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axogen pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

Axogen quarterly revenues are $48.6M, which are larger than IRIDEX quarterly revenues of $11.9M. Axogen's net income of -$3.8M is lower than IRIDEX's net income of -$1.7M. Notably, Axogen's price-to-earnings ratio is -- while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axogen is 2.55x versus 0.33x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -7.9% compared to Axogen's net margin of -35.24%. Axogen's return on equity of -7.2% beat Myomo's return on equity of -38.11%.

Axogen has a consensus price target of $24.43, signalling upside risk potential of 120.67%. On the other hand Myomo has an analysts' consensus of $9.05 which suggests that it could grow by 191%. Given that Myomo has higher upside potential than Axogen, analysts believe Myomo is more attractive than Axogen.

Axogen has a beta of 1.195, which suggesting that the stock is 19.457% more volatile than S&P 500. In comparison Myomo has a beta of 1.633, suggesting its more volatile than the S&P 500 by 63.336%.

Axogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axogen pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Axogen quarterly revenues are $48.6M, which are larger than Myomo quarterly revenues of $9.8M. Axogen's net income of -$3.8M is lower than Myomo's net income of -$3.5M. Notably, Axogen's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axogen is 2.55x versus 3.13x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of -7.9% compared to Axogen's net margin of -77.93%. Axogen's return on equity of -7.2% beat Stereotaxis's return on equity of -174.6%.

Axogen has a consensus price target of $24.43, signalling upside risk potential of 120.67%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 117.39%. Given that Axogen has higher upside potential than Stereotaxis, analysts believe Axogen is more attractive than Stereotaxis.

Axogen has a beta of 1.195, which suggesting that the stock is 19.457% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.461, suggesting its more volatile than the S&P 500 by 46.088%.

Axogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axogen pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

Axogen quarterly revenues are $48.6M, which are larger than Stereotaxis quarterly revenues of $7.5M. Axogen's net income of -$3.8M is higher than Stereotaxis's net income of -$5.8M. Notably, Axogen's price-to-earnings ratio is -- while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axogen is 2.55x versus 6.49x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.